1997
DOI: 10.1016/s1073-4449(97)70018-9
|View full text |Cite
|
Sign up to set email alerts
|

Transport Characteristics of the Slow Therapies: Implications for Achieving Adequacy of Dialysis in Acute Renal Failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
15
1
2

Year Published

2000
2000
2016
2016

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(18 citation statements)
references
References 19 publications
0
15
1
2
Order By: Relevance
“…CVVHD allows independent regulation of blood, dialysate, and ultrafiltrate flow rates, and clearance of solute during CVVHD is comprised of both a diffusive component and a convective (or ultrafiltration) component (23). Since net Q UF ranged from 3.0 to 9.2% of nominal Q DI during the CVVHD segment of this study, the observed ceftazidime clearances predominantly reflect the effects of alterations in blood and dialysate flow on diffusion across the membrane.…”
Section: Discussionmentioning
confidence: 81%
See 2 more Smart Citations
“…CVVHD allows independent regulation of blood, dialysate, and ultrafiltrate flow rates, and clearance of solute during CVVHD is comprised of both a diffusive component and a convective (or ultrafiltration) component (23). Since net Q UF ranged from 3.0 to 9.2% of nominal Q DI during the CVVHD segment of this study, the observed ceftazidime clearances predominantly reflect the effects of alterations in blood and dialysate flow on diffusion across the membrane.…”
Section: Discussionmentioning
confidence: 81%
“…(14) observed a value of 0.80 with a Fresenius F-40 filter. These data suggest that the choice among these three filter membranes is not a critical determinant of CVVHD performance for control of azotemia (23).…”
Section: Discussionmentioning
confidence: 86%
See 1 more Smart Citation
“…Step 4: Determine the timing for achievement of goal and monitoring parameters (FUN/BUN ratio) [30] . Anticoagulation efficacy should be frequently monitored using APTT or anti-Xa levels for heparin or low molecular weight heparin anticoagulation, and post-filter calcium for citrate-based anticoagulation.…”
Section: Monitoringmentioning
confidence: 99%
“…So könnte, bei mäßig erhöhter Harnstoffproduktionsrate, auch beim kritisch Kranken die Harnstoffkonzentration im Serum auf <150 mg/dl abgesenkt werden. Tatsäch-lich existiert aber kein evaluierter Wert, auf den die Harnstoffkonzentration im Serum abgesenkt werden sollte; ein Zielwert von 100-120 mg/dl, der auf dem Boden retrospektiver Daten vorgeschlagen wurde[20,25], ist bei hyperkatabolen Patienten nur durch eine sehr intensive Therapie erreichbar.E Es gilt andererseits als sicher, dass die Überlebenschancen von Patienten mit ANV von der Dosis der extrakorporalen Therapie abhängen. ml/kg/h verglichen.…”
unclassified